Skip to main content

Table 2 Comparison of clinical features of recurrence and non-recurrence in MOG-Ab-positive ADS

From: Clinical characteristics and prognosis of pediatric myelin oligodendrocyte glycoprotein antibody-associated diseases in China

 

Disease relapse group

Non-disease relapse group

P

 

5

25

 

Initial treatment time, d

12 (7–18)

13 (8–44)

0.379

Age at onset, years

6 ± 3

7 ± 4

0.584

MOG-Ab titer prognosis

  

0.009*

 Non-recurrence

0

17

 

 Recurrence

5

8

 

Disease duration, d

300 (248–1658)

150 (53–330)

0.006*

  1. ADS acquired demyelinating syndrome, MOG-Ab myelin oligodendrocyte glycoprotein antibody
  2. *Statistically significant (P < .05)
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us